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ABSTRACT 
 
There has been a significantly increased interest in the adoption of prediction modeling by 
many disease and case management programs to risk stratify members in order to optimize 
the utilization of available clinical resources. Before adopting any prediction model, it is crit- 
ical to understand how to evaluate the model’s accuracy. This paper explains the basic con- 
cepts of prediction accuracy, the relevant parameters, their drawbacks, and their interpreta- 
tions. It also introduces a new accuracy parameter termed “cost concentration,” which indicates 
the model accuracy more explicitly in the context of disease management.  
 
 
 
INTRODUCTION 
t is a well-known fact that a relatively small 
segment of the population is responsible for 
the majority of medical costs. For example, 20% 
of the population may be responsible for 80% 
of medical costs.1  Based on this fact, disease 
management enterprises could manage a large 
portion of costs by directing resources toward 
a small segment of the population. However, 
the current high-cost members are not neces- 
sarily  the  high-cost  members  of  the  future. 
Therefore, the object of using prediction mod- 
els in disease management is to try to identify 
the small segment of the population that will 
be responsible for a bigger percentage of the 
cost before it happens, so that preventive ac- 
tion can be taken. 
In this context, the prediction model with 
higher accuracy should be the model which 
identifies the smaller segment of the popula- 
tion that is responsible for a bigger percentage 
of the overall cost before costs are incurred. 
However, there is no established statistical 
term that explicitly evaluates prediction model 
accuracy in this way. Therefore, we define a 
new term we are calling “cost concentration.” 
Before introducing this new model-accuracy 
term, it is necessary to explain the traditional 
parameters used to evaluate prediction accu- 
racy and to explain their inherent shortcomings 
in the disease management context. 
 
 
TRADITIONAL PARAMETERS 
 
Individual R-Squared (R2) for continuous outcomes 
When the outcome of the prediction model 
is a continuous variable, such as money spent, 
the prediction accuracy is determined by mea- 
suring how close each individual predicted 
cost is to the actual observed cost.2 The sta- 
tistical   term   for   the   accuracy   measure   is 
 
 
 
 
 
R-squared (R2). R2 indicates the percentage of 
the total variation among individual observed 
costs that can be explained by the model. Its 
value ranges between 0 (0%) and 1 (100%). A 
value of 0 indicates that the model explains 
none of the variation in the costs, while a value 
of 1 indicates that the model explains all of the 
variation. This perfect fit, in which each pre- 
dicted cost equals each actual cost is, in reality, 
unattainable due to many random and unpre- 
dictable factors. 
R2 is a single summary measure of predic- 
tive accuracy. Its usage has been widely ac- 
cepted and understood in the statistical field. 
In the context of disease management, how- 
ever, R2 has several drawbacks. First, it reflects 
the model accuracy across the whole range of 
cost levels, while in disease management the 
interest is on the high-cost end only.3 In other 
words, we are more interested in how accurate 
the model is in terms of identifying high-cost 
users. We are less concerned about how closely 
the model rank orders members in the low-cost 
range. R2 cannot differentiate the model accu- 
racy at the high- or the low-cost end of the 
range. Second, R2 tends to be overly sensitive 
to the prediction error for individuals with very 
high costs because it squares the errors of pre- 
diction. This is a very important concern be- 
cause health expenditures typically have a very 
skewed distribution, where a small number of 
members have relatively large  expenditures. 
To overcome this problem, it has been sug- 
gested that the R2 should be calculated after 
truncating large medical expenditures.4 For ex- 
ample, we might set the ceiling value at $25,000 
or $50,000. The Society of Actuaries also sug- 
gests a new parameter called the “mean ab- 
solute prediction error.”3 Instead of squaring 
the error, mean absolute prediction error cal- 
culates the absolute value of the error, making 
it less sensitive to outlier values. 
Last, because of the unpredictable nature of 
medical expenditures, the R2 of even the best 
prediction model has an appearance of poor 
performance. For example, the R2 of a predic- 
tion model using administrative claims data is 
typically around 10%–20%. As a result, it can 
easily be interpreted that the model is only 
about 15% correct, or that it is about 85% wrong 
in predicting cost. This causes the healthcare 
decision makers to question the value of the 
prediction model, that is, “Why invest in an ex- 
pensive and complicated process that explains, 
at most, only 15% of the variation in costs,” or 
“Why use the prediction model to identify dis- 
ease management candidates when the model 
is only 15% right?” This misconception is 
caused by the flaw of using R2 to evaluate the 
accuracy of the prediction model. In the con- 
text of disease management, the objective of us- 
ing a prediction model is to try to identify the 
right group of members with whom to inter- 
vene. For example, if there are 100 patients who 
indeed become high-cost users and a predic- 
tion model predicts all of them, and only them, 
as predicted high-cost members, then this 
model should be regarded as perfect or 100% 
accurate. However, it does not necessarily have 
an R2 of 100%. In order to get R2 = 100%, the 
prediction model not only needs to predict 
members’ future costs in the right order but 
also to predict the exact amount correctly. The 
model with only 10%–20% R2 may still have 
fairly high accuracy in the context of stratify- 
ing risk, and the level of accuracy cannot be di- 
rectly reflected by the R2 value. Implying that 
the model is only 10%–20% right, or 80%–90% 
wrong, clearly is a wrong conclusion in this 
context. 
 
Sensitivity, specificity, positive predictive value, 
and ROC curve for dichotomous outcomes 
In the context of disease and case manage- 
ment, the target population of intervention is 
often predetermined. For example, the top 1% 
or 5% of the population or anyone with costs 
over $5000 may be chosen. As a result, the out- 
come can be defined as a dichotomous variable 
with two values, one for high cost (or positive) 
and one for low cost (or negative). In a similar 
manner, a cut-off point can be arbitrarily set in 
order to make any predicted cost into a di- 
chotomous variable as the predicted high-cost 
member and predicted low-cost member.5,6 
Sensitivity, specificity, positive predictive 
value, negative predictive value and Receiver 
Operating Characteristic (ROC) curves are a set 
of accuracy parameters dealing with dichoto- 
mous outcome. Because it is so easy to confuse 
the definitions of those parameters, it is help
 
ful to explain them using mathematical 
formulas first. 
Let us define four table cells as a, b, c, and d, 
where a is high cost and predicted high cost; b 
is low cost and predicted high cost; c is high 
cost and predicted low cost; and d is low cost 
and predicted low cost (Table 1). 
The following formulas then define the four 
terms noted above: 
 
Sensitivity = a/(a + c) 
Specificity = d/(b + d) 
Positive predictive value (PPV) = a/(a + b) 
Negative predictive value = d/(c + d) 
Sensitivity can be interpreted as the fraction of 
all true high-cost members that were predicted 
as high cost. Specificity is the fraction of all true 
low-cost members that were predicted as low 
cost. The opposites of sensitivity and specificity 
are also termed false negative rate (1 - sensi- 
tivity) and false positive rate (1 - specificity). 
It is important to keep in mind that the sensi- 
tivity and specificity both depend on the cut- 
off point used to define the predicted high cost 
and low cost. If the prediction cut-off thresh- 
old is set lower, then more members are pre- 
dicted to have high cost, and sensitivity will go 
up and specificity go down. Therefore it is dif- 
ficult to compare the sensitivity or the speci- 
ficity of two prediction models when the cut- 
off points are different. When the cut-off point 
is set, sensitivity and specificity are model spe- 
cific. 
The ROC curve is a measurement of model 
accuracy that is independent of the prediction 
cut-off point. The ROC curve is the curve of 
sensitivity versus 1 minus specificity across all 
prediction cut-off points. The area under the 
ROC curve indicates the predictive power of 
the model. Models can now be compared in- 
dependent of cut-off points. However, it is hard 
to interpret the meaning of the area under the 
ROC curve. 
Positive predictive value (PPV) is the fraction 
of all predicted high-cost members that are true 
high-cost members. The most common mistake 
in using PPV is not realizing that PPV is not 
only dependent on the model’s predictive 
power but is also dependent on the prevalence 
of true positives in the population. For exam- 
ple, we may apply a prediction model to two 
different populations. In one population, the 
top 1% of costs is defined as high cost. In the 
other population, the top 5% of costs is defined 
as high cost. Even when the models’ sensitiv- 
ity and specificity are constant, the PPV will be 
higher in the population in which the preva- 
lence of true positives is higher (the population 
where the top 5% is set as high cost). Negative 
predictive value works similarly with PPV but 
is seldom used in the risk stratification context 
because the positives are what we are inter- 
ested in. 
Sensitivity, specificity, and PPV may be more 
appealing than R2 as measures of prediction ac- 
curacy of a model because they focus on the ac- 
curacy of identifying potential high-cost users, 
which is directly relevant in the disease and 
case management setting. However, they have 
many drawbacks as well. First, as mentioned 
above, sensitivity, specificity, and PPV are all 
dependent on other conditions that have noth- 
ing to do with the prediction accuracy, such as 
high-cost prevalence and choice of prediction 
cut-offs. Because of this, it is very difficult to 
directly interpret the sensitivity and PPV and 
to compare different models. ROC is indepen- 
dent of the choice of prediction cut-offs, but the 
area under the ROC curve does not have a di- 
rect interpretation in terms of risk stratification. 
Like R2, it also measures accuracy over the 
whole range of costs, while only the high-cost 
subjects are of interest. Second, similar to R2, 
sensitivity and PPV also give the general im- 
pression of poor performance to a model. For 
example, most administrative claim-based pre- 
diction models have a PPV of around 30% 
when both the true high-cost and the predic- 
TABLE 1.   DEFINING TABLE CELLS FOR A MODEL THAT 
PREDICTS DICHOTOMOUS COST OUTCOMES  
 
Actual cost groups 
Predicted cost groups High cost Low cost 
High cost 
Low cost 
a 
c 
b 
d 
 
 
 
tion high-cost cut-offs are defined as the top 
5%. In other words, only about one third of the 
predicted high-cost members are true high cost 
(true positives), or two thirds of them are false 
positives. In the context of disease manage- 
ment, false positives may easily be interpreted 
as a waste of clinical resources on those who 
do not need the intervention. This certainly will 
make any healthcare decision maker question 
the real value of a prediction model. 
This apparent poor performance is caused by 
the intrinsic flaw of treating the outcome as di- 
chotomous. For example, if we predefine high 
risk as costs greater than or equal to $2000 a 
year, then two prediction models will not be 
differentiated if one predicts a $1999 member 
as positive and the other predicts a $0 member 
as positive. This is because they are both re- 
garded as false positives even though there are 
different magnitudes of misclassification be- 
tween the two. Simply regarding all false pos- 
itives as a waste of clinical resources is thus 
overly strict. In a similar manner, the correct 
classification also has different magnitude. For 
example, correctly identifying as high cost a 
member whose true cost is $2001 or another 
member whose true cost is $100,000 has the 
same contribution to the sensitivity and PPV. 
But they have different disease management 
implications. The sensitivity, specificity, and 
PPV are not able to differentiate the magnitude 
of misclassification (or correct classification). A 
prediction model could still have value even if 
it has a PPV of 0 (100% misclassification rate), 
as long as the misclassified members only miss 
the cut-off by a small amount. For example, as 
long as the model can identify a group of mem- 
bers with true costs higher than average, then 
the prediction model has value (or has some 
level of accuracy), even when the PPV or sen- 
sitivity may turn out to be 0% for a higher cut- 
off. 
 
 
NEW PARAMETER 
 
Cost concentration 
Because of the drawbacks of the traditional 
parameters in evaluating the accuracy of pre- 
diction models in the disease and case man- 
agement setting, we introduce a new parame- 
ter we are calling “cost concentration.” It is de- 
fined as the percentage of true cost of the total 
population that is concentrated among the sub- 
set of the population that was predicted to be 
high cost. For example, a given model may pre- 
dict 5% of the population as high cost. If a 
model had no predictive value at all, then we 
would expect that about 5% of the cost is con- 
centrated in that group. However, if the model 
was reasonably accurate, then this subset of the 
population may have a cost concentration of 
25%. The difference between the two percent- 
ages (from 5% to 25%) indicates the value of 
prediction model. 
Similar to sensitivity and PPV, in order to use 
cost concentration the prediction needs to be 
expressed as a dichotomous outcome, namely, 
predicted high cost versus predicted low cost. 
This makes it directly relevant in the disease 
management context. On the other hand, dif- 
ferent from the sensitivity and PPV which also 
expresses the outcome as dichotomous (true 
positive and true negative), the outcome of cost 
concentration is expressed as a continuous 
value of total cost among predicted high cost. 
This enables it to differentiate the magnitude 
of misclassification and correct classification. 
Cost concentration is expressed in the same 
way as Pareto’s principle of the “20% who ac- 
count for 80% of the cost.” Pareto’s principle 
also defines the highest possible value of cost 
concentration in a population. For example, a 
perfect prediction model might identify that 
20% of high-cost members who will account for 
80% of true future cost. The lowest cost con- 
centration value would be that 20% of the 
members who account for 20% of the cost, 
which represents an indifferent model (or ran- 
dom selection model), similar to the indifferent 
line in an ROC curve. 
By analysis of the cost distribution of typical 
health claim data, we defined the approximate 
highest cost concentration value at different 
cut-off points in Table 2, along with the cost 
concentration value of a typical prediction 
model based on claim data. 
The main advantage of using cost concen- 
tration is that it explicitly indicates the value of 
the prediction model in the context of disease 
management. For example, if a model has a cost 
 
TABLE 2.   COST CONCENTRATION AT DIFFERENT PREDICTION CUT-OFF POINTS 
aThis prediction model has an R2  of 25% while truncating the cost at $50,000, and both sensitivity and PPV of 
31% at the 5% cut-off point and an area under the ROC of 0.82. 
 
 
 
Prediction cut-off point (%) 1 5 10 15 20 
Highest cost concentration (%) 21 44 58 67 73 
Indifferent (lowest) cost concentration (%) 1 5 10 15 20 
Cost concentration of a prediction modela 8 22 35 44 52 
 
 
 
 
concentration of 25% among the 5% predicted 
high-cost members, then it means a disease 
management program that uses this model will 
be able to manage 25% of the total cost by fo- 
cusing on the 5% of the population. The value 
of the prediction model becomes intuitively 
simple. But with R2 or PPV of 0.3, it can be eas- 
ily and mistakenly interpreted as 30% correct 
and 70% wrong, as explained earlier. 
Another advantage of the cost concentration 
concept is its ability to take the magnitude of 
misclassification and correct classification into 
account. For example, model A and model B 
may have the same number of misclassifica- 
tions and correct classifications and therefore 
have the same values for sensitivity and PPV. 
However, model A may have a lower magni- 
tude of misclassification or a higher magnitude 
of correct classification, and therefore it has a 
higher cost concentration. In that case, model 
A should be regarded as a better model. 
Cost concentration has two main drawbacks. 
First, similar to sensitivity and PPV, its value 
depends on the prediction high-cost cut-off 
point. Therefore, the cost concentration is only 
comparable between models in which the cut- 
off point of predicted high cost is the same. Sec- 
ond, similar to R2 it is sensitive to outlier value. 
For example, correctly predicting a $1,000,000 
member as a high-cost member may have a 
strong impact on the cost concentration value, 
even though that member is just one true pos- 
itive. 
There could be a situation in which model 
A has higher cost concentration than model B 
but has significantly lower sensitivity and 
PPV than model B. There can be two reasons 
for this. One is that model A has more mis- 
classification but with less magnitude (the 
false positives have high true cost value but 
 
barely make the cut-off point as true positive), 
and model B has less misclassification but 
high magnitude (including some $0 cost 
members as predicted positive). Under this 
situation, the cost concentration is a better pa- 
rameter to balance the overall effect of the 
model, and we can conclude that model A still 
is better than model B. The other reason that 
causes this situation is that some outliers of 
true positive of model A may skew the cost 
concentration, meaning model A has a 
smaller number of true positives, but many of 
them have extremely high-cost value. Judg- 
ing which model is a better prediction model 
would be difficult in this situation. The com- 
bined information, including R2, area under 
ROC, sensitivity, PPV, cost concentration, 
and clinical consideration, need to be evalu- 
ated together to make the judgment. 
 
 
CONCLUSION 
 
There has been an increase of interest in us- 
ing prediction models in disease and case man- 
agement. However, a proper term for evaluat- 
ing the accuracy of prediction models in this 
context is lacking. Traditional model accuracy 
terms such as R-squared, sensitivity, PPV, and 
ROC all have significant limitations. The new 
term, “cost concentration,” appears to be a 
more appropriate term in evaluating model ac- 
curacy in this context. It is directly relevant to 
risk stratification, and it is intuitively easy to 
understand. Due to its own drawbacks, one still 
needs to be cautious in judging model accuracy 
solely by cost concentration, especially when 
there are significant discrepancies between cost 
concentration and the more traditionally used 
evaluation parameters. 
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